Pirfenidone for Pulmonary Fibrosis in Patients With CKD Does Not Hike Mortality
Patients with idiopathic pulmonary fibrosis and CKD have limited options for antifibrotic therapy. An observational study examined the use of the antifibrotic pirfenidone in patients with kidney disease (CKD) and pulmonary fibrosis.
South Korea Soult Ukpyolsi Kyonggi Do Yong Hyun Kim Korean National Health Insurance Service Catholic University Of Korea
Source: renalandurologynews.com